FILING ANALYSIS · THURSDAY, AUGUST 6
Vivoryon Therapeutics Nv 0R3M — RNS
neutral
Vivoryon Therapeutics N.V. reported a net loss of EUR 3.4 million for H1 2026 and maintained its financial guidance, with cash expected to fund operations into Q4 2026. The company is pursuing strategic partnerships, including advanced term sheet negotiations for a potential licensing agreement, but no quantified surprise was disclosed.
The filing
Vivoryon Therapeutics Nv — Vivoryon Therapeutics N V Reports H1 2026 Fi
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →